EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SNX10 deficiency impairs sensitivity to anti-HER2 antibody–drug conjugates via altering HER2 trafficking in HER2-positive breast cancer

Yu-Fei Chen iD, Qing-Hua Zhang, Zhong-Wei Zhang, Yu-Jie Zhou, Cui-Cui Liu, Zhi-Ming Shao, Ke-Da Yu iD

Proceedings of the National Academy of Sciences · 22.04.2025 · 122 (16)

DOI: 10.1073/pnas.2417586122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 14.04.2025. Verfasst von Yu-Fei Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Fudan University Shanghai Cancer Center and Cancer Institute, Shanghai 200032, People's Republic of China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Immunoconjugates, Sorting Nexins. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs), Ministry of Health of China | Wu Jieping Medical Foundation (WJMF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) are a rapidly developing therapeutic approach in cancer treatment that has shown remarkable efficacy in breast cancer. Despite the promising efficacy of anti-HER2 ADCs, many patients are still experiencing disease progression under treatment. Here, by analyzing the transcriptome data from patient-derived organoid models, I-SPY2 trial, and resistant cell lines, we identified that SNX10 deficiency conferred anti-HER2 ADCs resistance in HER2-positive breast cancer. Low levels of SNX10 attenuated HER2 recycling and promoted HER2 trafficking into lysosomes. Furthermore, we found the underlying mechanism of SNX10 in HER2 traffic by regulating the endosomal RAB11A. We propose that SNX10 deficiency contributes to the inhibition of HER2 recycling as well as the decrease of cell-surface HER2 and causes anti-HER2 ADC resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBreast NeoplasmsImmunoconjugatesSorting NexinsHumansFemaleDrug Resistance, NeoplasmCell Line, TumorProtein Transportrab GTP-Binding ProteinsLysosomesEndosomes

Stichwörter der Autor:innen

antibody–drug conjugatesbreast cancerdrug resistance

Substanzen

Erb-b2 Receptor Tyrosine KinasesImmunoconjugatesSorting Nexinsrab GTP-Binding ProteinsERBB2 protein, human

Autor:innen und Institutionen

  • Department of Breast Surgery, Fudan University Shanghai Cancer Center and Cancer Institute, Shanghai 200032, People's Republic of China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, People's Republic of China.
  • Department of Intensive Care Unit, Fudan University Shanghai Cancer Center, Shanghai 200032, People's Republic of China.

ORCID-Profile: Yu-Fei Chen, Ke-Da Yu

Förderung

  • MOST | National Key Research and Development Program of China (NKPs)
  • Ministry of Health of China | Wu Jieping Medical Foundation (WJMF)

Zitieren

APA

Chen, Y. F., Zhang, Q. H., Zhang, Z. W., Zhou, Y. J., Liu, C. C., Shao, Z. M., & Yu, K. D. (2025). SNX10 deficiency impairs sensitivity to anti-HER2 antibody–drug conjugates via altering HER2 trafficking in HER2-positive breast cancer. Proceedings of the National Academy of Sciences, 122(16). https://doi.org/10.1073/pnas.2417586122

Vancouver

Chen YF, Zhang QH, Zhang ZW, Zhou YJ, Liu CC, Shao ZM, et al. SNX10 deficiency impairs sensitivity to anti-HER2 antibody–drug conjugates via altering HER2 trafficking in HER2-positive breast cancer. Proceedings of the National Academy of Sciences. 2025;122(16). doi:10.1073/pnas.2417586122

BibTeX
@article{Chen2025,
  author = {Chen, Yu-Fei and Zhang, Qing-Hua and Zhang, Zhong-Wei and Zhou, Yu-Jie and Liu, Cui-Cui and Shao, Zhi-Ming and Yu, Ke-Da},
  title = {SNX10 deficiency impairs sensitivity to anti-HER2 antibody–drug conjugates via altering HER2 trafficking in HER2-positive breast cancer},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {16},
  doi = {10.1073/pnas.2417586122}
}
Kostenlos starten →